Literature DB >> 20031265

Ondansetron use in the pediatric emergency department and effects on hospitalization and return rates: are we masking alternative diagnoses?

Jesse J Sturm1, Daniel A Hirsh, Adam Schweickert, Robert Massey, Harold K Simon.   

Abstract

STUDY
OBJECTIVE: We evaluate the effect of ondansetron use in cases of suspected gastroenteritis on the proportion of hospital admissions and return visits and assess whether children who receive ondansetron on their initial visit to the pediatric emergency department (ED) for suspected gastroenteritis return with an alternative diagnosis more frequently than those who did not receive ondansetron.
METHODS: This is a retrospective review of visits to 2 tertiary care pediatric EDs with an International Classification of Diseases, Ninth Revision diagnosis of vomiting or gastroenteritis. A logistic regression model was developed to determine the effect of ondansetron use during the initial pediatric ED visit on hospital admission, return to the pediatric ED within 72 hours, and admission on this return visit. For patients who returned within 72 hours and were admitted, hospital discharge records were reviewed. The proportions of alternative diagnoses, defined as a hospital discharge diagnosis that was not a continuation of gastroenteritis or vomiting, were compared between the groups.
RESULTS: During the 3-year study period (2005 to 2007), 34,117 patients met study criteria. Ondansetron was used for 19,857 (58.2%) of these patients on their initial pediatric ED visit. After controlling for differences between the groups, patients who received ondansetron were admitted on their initial visit less often: odds ratio (OR) 0.47 (95% confidence interval [CI] 0.42 to 0.53). However, those who received ondansetron were more likely to return to the pediatric ED within 72 hours (OR 1.45; 95% CI 1.27 to 1.65) and be admitted on the return visit (OR 1.74; 95% CI 1.39 to 2.19). The proportions of alternative diagnoses at hospital discharge were not significantly different in the group that received ondansetron on the initial pediatric ED visit (14.9%) compared with the group that did not (22.4%) (absolute difference 7.5% [95% CI -0.5% to 16.4%).
CONCLUSION: Ondansetron use in the pediatric ED reduces hospital admissions for suspected gastroenteritis and vomiting. However, children who receive ondansetron in the pediatric ED appear more likely to return to the pediatric ED and be admitted on this return visit than their counterparts. Furthermore, the use of ondansetron does not appear to be associated with increased risks of masking serious diagnoses in children. Copyright 2009 American College of Emergency Physicians. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20031265     DOI: 10.1016/j.annemergmed.2009.11.011

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  5 in total

1.  A supplementary home dose of oral ondansetron given in anticipation of recurrent emesis in paediatric acute gastroenteritis.

Authors:  Mark Xu; Michael Rieder
Journal:  Paediatr Child Health       Date:  2014-02       Impact factor: 2.253

2.  Oral ondansetron administration in emergency departments to children with gastroenteritis: an economic analysis.

Authors:  Stephen B Freedman; Michael J Steiner; Kevin J Chan
Journal:  PLoS Med       Date:  2010-10-12       Impact factor: 11.069

3.  Variables Associated With Intravenous Rehydration and Hospitalization in Children With Acute Gastroenteritis: A Secondary Analysis of 2 Randomized Clinical Trials.

Authors:  Naveen Poonai; Elizabeth C Powell; David Schnadower; T Charles Casper; Cindy G Roskind; Cody S Olsen; Phillip I Tarr; Prashant Mahajan; Alexander J Rogers; Suzanne Schuh; Katrina F Hurley; Serge Gouin; Cheryl Vance; Ken J Farion; Robert E Sapien; Karen J O'Connell; Adam C Levine; Seema Bhatt; Stephen B Freedman
Journal:  JAMA Netw Open       Date:  2021-04-01

4.  Improving ondansetron use and oral rehydration instructions for pediatric acute gastroenteritis.

Authors:  Perseus Vistasp Patel; Thomas Wallach; Glenn Rosenbluth; Mel Heyman; Sofia Verstraete
Journal:  BMJ Open Qual       Date:  2022-03

5.  Evaluating outcomes associated with a discharge action plan employing single-dose home use of ondansetron in patients with acute gastroenteritis.

Authors:  Elizabeth Haines; Robert van Amerongen; Robert Birkhahn; Wendy Wen; Theodore Gaeta
Journal:  Open Access Emerg Med       Date:  2012-03-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.